Episode Summary
Executive Summary: Morningstar’s healthcare strategists discuss the sector’s biggest themes: the rise of anti-obesity GLP-1 drugs, AI’s incremental but meaningful role in care delivery and drug development, consumerization of healthcare, value-based care, and the sector’s investment outlook. They also weigh patent cliffs, political/regulatory risk, and why healthcare has lagged broader markets despite major innovation.
Main Topics: Anti-obesity GLP-1 drugs and ecosystem impact (Priority: 5/5): Damian and Rebecca describe GLP-1 obesity therapies as a major healthcare breakthrough, with massive market potential, clear winners in Novo Nordisk and Eli Lilly, and spillover effects on insulin, cardiovascular care, telehealth, and employer benefits. AI in healthcare (Priority: 5/5): Rebecca frames AI as significant but not transformative overnight: strongest near-term use cases include ambient clinical documentation and drug discovery acceleration, but workflow, oversight, and integration challenges remain. Consumerization of healthcare (Priority: 4/5): The conversation highlights patient demand for convenience and control, driving growth in retail health, home care, wearables, consumer-grade monitoring, and med spas. Value-based care and prevention (Priority: 4/5): Rebecca emphasizes the push to realign incentives away from fee-for-service toward prevention, early screening, and coordinated care, aided by technology and employer partnerships. Healthcare investing performance and moats (Priority: 4/5): Damian explains that healthcare’s weak index performance has been driven mainly by biopharma and pricing pressures, while structural moats, patents, and innovation still support attractive long-term franchises. Politics, regulation, and private equity scrutiny (Priority: 3/5): The guests discuss muted election risk for public healthcare stocks, but growing regulatory scrutiny of private equity in healthcare, especially around transparency and provider ownership. Innovation cycles and patent cliffs (Priority: 3/5): Damian argues healthcare moats depend on continual innovation in drugs, devices, and diagnostics; the next major patent pressure point is expected around 2028, but not as severe as earlier cliffs.
Key Arguments: GLP-1 obesity drugs are a major step-change in efficacy, moving from roughly 5% weight loss to about 20%, which supports a potential multibillion-dollar market. Novo Nordisk and Eli Lilly are the clear first-mover winners in obesity treatment, but they also partially offset potential insulin losses because they dominate both categories. Broader healthcare beneficiaries include telehealth, pharmacies, employers, and companies offering lifestyle and medication-management tools around obesity treatment. AI will likely improve healthcare in discrete areas first—such as documentation, triage, and drug discovery—rather than instantly “fixing” the whole system. Ambient clinical documentation can save physician time, but productivity gains may be absorbed by higher patient volume rather than lower burnout. Value-based care seeks to reverse fee-for-service incentives by rewarding prevention and coordinated care, and AI/data tools are making that model more feasible. Healthcare’s underperformance versus the market is largely a biopharma story tied to pricing pressure and PBM bargaining power, not a broad failure of the whole sector. Despite political rhetoric, the 2024 election is unlikely to produce major new pressure on healthcare stocks because Medicare drug reform has already reduced some of the prior policy overhang. Private equity is still active in healthcare, but mostly in fragmented outpatient categories rather than hospitals or nursing homes, which have been less attractive for years. Healthcare moats depend on patents, know-how, and continual R&D; innovation is the central defense against commoditization and margin compression.
Data Points: Projected annual GLP-1 sales: Close to $175 billion per year - Damian’s estimate for the obesity/GLP-1 drug class over the next decade Weight-loss efficacy before current wave: About 5% - Previous generation obesity therapies Weight-loss efficacy with current wave: About 20% - New GLP-1 drugs R&D spending in biopharma: Close to 20% of sales - Damian notes this as one of the most R&D-intensive industries Patent exclusivity duration: About 20 years - Damian explains patents as a key source of moat protection Medicare healthcare cost projection: $1.7 trillion by end of 2030 - Rebecca cites this in discussing unsustainable U.S. spending Current U.S. healthcare spending: About $4.5 trillion - Rebecca cites this as roughly 20% of GDP U.S. healthcare spending share of GDP: Close to 20% - Rebecca discusses the macro burden of healthcare costs U.S. spending vs OECD average: More than twice the OECD average per capita - Rebecca contrasts U.S. costs and outcomes with peer nations Morningstar healthcare public coverage scope: Global, with emphasis on developed economies - Damian describes the team’s coverage universe PitchBook healthcare analyst team size: About 35 analysts - Rebecca describes the institutional research group Private investment share in healthcare: About 25% of U.S. venture dollars and about 14% of private equity dollars - Rebecca quantifies healthcare’s share of private capital flows Last major private equity hospital deal: 2018 - Rebecca says hospitals have largely fallen off PE’s radar Expected patent pressure: By 2028 - Damian describes a “patent hill or slope” rather than a cliff Last major patent cliff period: 2010 to 2012 - Damian compares current outlook to the prior cliff
Pivotal Quotes: "This is probably one of the most important innovations themes we've seen in healthcare in a long time." — Damian Conover: On the significance of GLP-1 obesity drugs "We think that this new obesity drug class is one of the biggest forces shaping healthcare right now." — Rebecca Springer: On the broad system-wide impact of GLP-1s "AI is really exciting, right? AI allows you to do science much more quickly. It gets you to a drug candidate faster, but doesn't necessarily prove that candidate is going to work." — Rebecca Springer: On the limits of AI in drug development
Implications: Investors should expect continued healthcare innovation, but returns will depend on pricing, regulation, and valuation discipline. GLP-1s, AI, and consumer health offer growth, while biopharma, PE-backed providers, and higher-profile names face scrutiny.
About The Long View
Expand your investing horizons and look to the long term. Join hosts Christine Benz, Dan Lefkovitz, and Amy C. Arnott as they talk to influential leaders in investing, advice, and personal finance about a wide-range of topics, such as asset allocation and balancing risk and return.